Peter de Waele
Vorstandsvorsitzender bei Advanced Therapies Consulting Limited
Aktive Positionen von Peter de Waele
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Advanced Therapies Consulting Limited | Vorstandsvorsitzender | - | - |
Karriereverlauf von Peter de Waele
Ehemalige bekannte Positionen von Peter de Waele
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CELYAD ONCOLOGY SA | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2010 | - |
| Corporate Officer/Principal | 01.11.2010 | - | |
| Xcellentis NV | Geschäftsführer | 01.01.2006 | 01.01.2006 |
| Gründer | 01.01.2006 | 01.01.2006 | |
| Ghent University | Corporate Officer/Principal | 01.01.1986 | 01.01.1986 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - | - |
Ausbildung von Peter de Waele
| Ghent University | Doctorate Degree |
Statistik
International
| Belgien | 5 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Chief Operating Officer | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
| Xcellentis NV | Health Technology |
| Advanced Therapies Consulting Limited |
- Börse
- Insiders
- Peter de Waele
- Erfahrung
